SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

March 23, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with platinum- and fluoropyrimidine-based chemotherapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation.

Download PDF